Sigilon Therapeutics (SGTX) Stock Price, News & Analysis

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sigilon Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SGTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGTX, but not buy additional shares or sell existing shares.
View SGTX analyst ratings or view top-rated stocks.

2 brokerages have issued 12 month price objectives for Sigilon Therapeutics' shares. Their SGTX share price targets range from $21.00 to $21.00. On average, they expect the company's share price to reach $21.00 in the next year. This suggests that the stock has a possible downside of 6.5%.
View analysts price targets for SGTX or view top-rated stocks among Wall Street analysts.

Sigilon Therapeutics, Inc. (NASDAQ:SGTX) announced its earnings results on Wednesday, November, 10th. The company reported ($8.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($8.58) by $0.39. The business had revenue of $1.95 million for the quarter, compared to analyst estimates of $3.20 million. Sigilon Therapeutics had a negative trailing twelve-month return on equity of 83.07% and a negative net margin of 171.29%.

Sigilon Therapeutics shares reverse split before market open on Tuesday, May 23rd 2023. The 1-13 reverse split was announced on Tuesday, May 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Sigilon Therapeutics (SGTX) raised $101 million in an IPO on Friday, December 4th 2020. The company issued 5,600,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, Jefferies, Barclays and Canaccord Genuity acted as the underwriters for the IPO.